It has long been clear that tumors that are restricted to the tissue of origin at the time of initial diagnosis carry a relatively good prognosis, and often have five-year survival rates that exceed 90%. Conversely, when the tumor has spread to distant sites at the time of diagnosis, the prognosis is often poor, with five-year survival rates of less than 10%. These observations highlight the importance of the metastatic spread of the cancer cells in the overall battle against cancer, and by extension, in the evaluation of novel anti-cancer compounds. Coupled with this, is growing evidence that tumor cell behavior can be different when the tissue is non-homologous to the tumor tissue type . These observations create a compelling case for the evaluation of any novel anti-cancer compound in a metastatic model of cancer.

To meet the need for these models, Biomodels offers models of metastatic breast cancer. We evaluate metastatic spread to the lung and the bone histologically.